As of Friday close, Intercept Pharmaceuticals Inc.’s (NASDAQ:ICPT) stock was up $0.46, moving up 4.60 percent to $10.45. The average number of shares traded per day over the past five days has been 543,920 shares. 4 times new highs have been achieved over the past 5 days, with a -$0.03 fall in that time frame. In the last twenty days, the average volume was 704,560, while in the previous 50 days, it was 1,027,190.
Since last month, ICPT stock retreated -2.88%. Shares of the company fell to $9.70 on 08/14/23, the lowest level in the past month. A 52-week high of $21.86 was reached on 02/08/23 after having rallying from a 52-week low of $8.82. Since the beginning of this year, ICPT’s stock price has dropped by -15.52% or -$1.92, and marked a new high 16 times. However, the stock has declined by -52.20% since its 52-week high.
Valuation Metrics
The stock’s beta is 1.22. Besides these, the trailing price-to-sales (P/S) ratio of 1.39, the price-to-book (PB) ratio of 6.45.
Financial Health
In the three months ended June 29, Intercept Pharmaceuticals Inc.’s quick ratio stood at 2.50, while its current ratio was 2.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 3.31, and the total debt-to-equity ratio was 4.94. On the profitability front, the trailing twelve-month gross margin is 99.70% percent. In the year ended June 29, EBITDA margin amounted to -23.09%, whereas operating margins totaled -51.80%. Based on annual data, ICPT earned $284.73 million in gross profit and brought in $285.71 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -37.60%. Return on equity (ROE) for the past 12 months was 248.80%.
In Intercept Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $223.6 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ICPT’s revenue rose 14.29% to $67.96 million during the quarter, while net income inched up to $83.72 million. While analysts expected Intercept Pharmaceuticals Inc. to report -$0.51 quarterly earnings, the actual figure was -$0.14 per share, beating the consensus estimate by 72.50%. During the quarter, the company generated -$8.98 million in EBITDA. The liabilities of Intercept Pharmaceuticals Inc. were 417.09 million at the end of its most recent quarter ended June 29, and its total debt was $333.41 million. The value of shareholders’ equity is $41.78 million.
Technical Picture
This quick technical analysis looks at Intercept Pharmaceuticals Inc.’s (ICPT) price momentum. With a historical volatility rate of 46.27%, the RSI 9-day stood at 50.77% on 18 August.
With respect to its five-day moving average, the current Intercept Pharmaceuticals Inc. price is down by -0.29% percent or -$0.03. At present, ICPT shares trade +0.10% above its 20-day simple moving average and -22.36% percent below its 100-day simple moving average. However, the stock is currently trading approximately -12.70% below its SMA50 and -27.08% below its SMA200.
Stochastic coefficient K was 26.05% and Stochastic coefficient D was 24.58%, while ATR was 0.48. Given the Stochastic reading of 43.10% for the 14-day period, the RSI (14) reading has been calculated as 47.47%. As of today, the MACD Oscillator reading stands at -0.10, while the 14-day reading stands at -0.26.
Analyst Ratings
H.C. Wainwright upgraded its rating on Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) to a Buy in a note to investors on July 13, 2023. The analysts firm previously had a Sell rating on the stock.Intercept Pharmaceuticals Inc. (ICPT) has been rated Hold by analysts. According to 1 brokerage firm, ICPT is a sell, and 9 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Intercept Pharmaceuticals Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $13.50, the current consensus forecast for the stock is $10.00 – $20.00. Based on these forecasts, analysts predict Intercept Pharmaceuticals Inc. (ICPT) will achieve an average price target of $14.67.
